Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
The Roche/Genentech oncology pipeline includes 40 investigational cancer medicines being studied in 600 clinical trials across a dozen types of cancer. ... an anti-NaPi2b antibody-drug-conjugate ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner ...
oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 trastuzumab: breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ...
FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer -- New Personalized Medicine Helped People in ...
Pages in category "Drugs developed by Genentech" The following 102 pages are in this category, out of 102 total. This list may not reflect recent changes. A.
Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery. [1] [2] [3]
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer Phase III data from the CLL11 study to ...